Basic Information
| LncRNA/CircRNA Name | PLK4 |
| Synonyms | polo-like kinase 4 associated lncRNA |
| Region | NA |
| Ensemble | NA |
| Refseq | NA |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | Talazoparib | ||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | hepatocellular carcinoma |
| ICD-0-3 | C22.0 |
| Methods | Microarray, qPCR, Luciferase reporter assay etc. |
| Sample | liver tumour tissues,cell lines (HepG2, Huh-7, LX2, LO2 and SMCC-7721) |
| Expression Pattern | down-regulated |
| Function Description | In this study, we identified a novel function lncRNA, named polo-like kinase 4 associated lncRNA (lncRNA PLK4, GenBank Accession No. RP11-50D9.3), whose expression was dramatically down-regulated in hepatocellular carcinoma (HCC) tissues and cells. Interestingly, talazoparib, a novel and highly potent poly-ADP-ribose polymerase 1/2 (PARP1/2) inhibitor, could increase lncRNA PLK4 expression in HepG2 cells. Importantly, we showed that talazoparib-induced lncRNA PLK4 could function as a tumour suppressor gene by Yes-associated protein (YAP) inactivation and induction of cellular senescence to inhibit liver cancer cell viability and growth. In summary, our findings reveal the molecular mechanism of talazoparib-induced anti-tumor effect, and suggest a potential clinical use of talazoparib-targeted lncRNA PLK4/YAP-dependent cellular senescence for the treatment of HCC. |
| Pubmed ID | 32243714 |
| Year | 2020 |
| Title | A Novel lncRNA PLK4 Up-Regulated by Talazoparib Represses Hepatocellular Carcinoma Progression by Promoting YAP-mediated Cell Senescence |
External Links
| Links for PLK4 | GenBank HGNC NONCODE |
| Links for hepatocellular carcinoma | OMIM COSMIC |